Yoo, M., Nelson, R., Dougherty, M., Lee, H., Gutowski, R., Kohli, M. (2026). Cost effectiveness of eight first-line regimens in metastatic hormone-sensitive prostate cancer (mHSPC) including niraparib + abiraterone acetate/prednisone.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.47